Spyre Therapeutics, Inc.SYREEarnings & Financial Report
Nasdaq
SYRE Q4 2024 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-61.3M
Net Profit
$-56.3M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
Spyre Therapeutics, Inc. Q4 2024 Financial Summary
Spyre Therapeutics, Inc. reported revenue of $0 for Q4 2024, with a net profit of $-56.3M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-56.3M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 2024 |
Spyre Therapeutics, Inc. Annual Revenue by Year
Spyre Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $0).
| Year | Annual Revenue |
|---|---|
| 2024 | $0 |
| 2023 | $886.0K |
| 2022 | $2.3M |
Income Statement
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $198000 | $688000 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | -85.5% | 10.1% | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $52.5M | $243.5M | $207.3M | $341.9M | $487.6M | $436.1M | $421.1M | $608.5M |
| Liabilities | $18.8M | $253.6M | $65.6M | $73.3M | $81.9M | $61.7M | $93.7M | $90.7M |
| Equity | $33.7M | $-207.4M | $-245.4M | $184.0M | $152.3M | $374.4M | $327.4M | $517.8M |
Cash Flow
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-17.6M | $-16.6M | $-34.6M | $-31.0M | $-28.5M | $-62.2M | $-29.4M | $-37.2M |